SciRisk 100 · Pharmaceuticals & Biotechnology · Rank 26 of 100

Novartis

NVS · Switzerland · Pharmaceuticals & Biotechnology SC5 Very High

Economic Supply Chain Risk Capital

$116.3m

95% one-year Value-at-Risk · interval $113.4m to $119.1m (4.9% wide)

Risk Capital Intensity

0.258%

of $45.0bn revenue · 7th highest in the index

Global rank

#26

of 100 by ESCRC

Sector rank

#7

of 10 in Pharmaceuticals & Biotechnology

Expected Shortfall

$185.8m

Mean loss beyond ESCRC

Expected annual loss

$30.3m

Ordinary year

Revenue / COGS

45.0 / 9.0

USD bn · gross margin 80%

Suppliers modelled

13

3 correlated geographies

What does this ESCRC number mean?

An ESCRC of $116.3m is the estimated economic supply-chain risk capital requirement generated by the SciRisk ESCRC model for Novartis under the stated assumptions: a 365-day horizon, 100,000 simulated years, and the 95% tail of the resulting loss distribution. Beyond that threshold the average loss — the Expected Shortfall — is $185.8m; in an ordinary year the expected loss is $30.3m.

Value-at-Risk: the portfolio loss not exceeded with the chosen confidence level. Read as the ESCRC risk capital — the loss the firm should be prepared to absorb in a bad year. Model-implied and intended for screening and ranking, not a calibrated capital figure.

Supply Chain Risk Capital Profile

Where the risk capital comes from. Every column is a production-engine output for this network — nothing is inferred.

By tier

Tier 1

82%

Tier 2

15%

Tier 3

2%

Share of summed standalone VaR. Deeper tiers are attenuated by the engine's echelon buffer factors and capped by flow conservation.

By supplier geography

Switzerland

66%

Germany

18%

USA

6%

UK

6%

China

4%

Major-event risk is correlated within a geography group (rho = 0.35), so concentration here compounds.

By supplier industry

pharma bio

95%

general mfg

5%

chemicals materials

0%

Buckets are the calibrated-priors industry classes that set each supplier's minor-event rate.

Largest supplier share

45%

Lonza Group

Top-3 concentration

72%

of summed standalone VaR

Tier-1 share of risk

82%

Direct suppliers

Diversification benefit

41.0%

vs. sum of standalone VaR

Supplier	Tier	Country	ExposureUSD m	Standalone VaRUSD m	Expected lossUSD m	Tail intensityrevenue-days	RoESCRCx
Lonza GroupCAR-T cell therapy mfg	T1	Switzerland	1500	88.8	13.9	4.3	67.4
SiegfriedAPI manufacturing	T1	Switzerland	600	35.5	5.6	4.3	67.4
RentschlerBiologics CMO	T1	Germany	300	17.8	2.8	4.3	67.4
Oxford BiomedicaLentiviral vectors	T1	UK	200	11.8	1.9	4.3	67.4
SartoriusBioprocess equipment	T2	Germany	300	10.7	1.7	4.3	67.4
Thermo FisherRaw materials/equipment	T1	USA	500	8.7	0.8	1.3	229.5
WuXi AppTecCRO/CMO services	T2	China	250	7.2	1.0	3.5	83.8
Merck KGaACell culture media	T2	Germany	200	7.1	1.1	4.3	67.4
BachemPeptide API	T2	Switzerland	150	5.3	0.9	4.3	67.4
CytivaBioprocessing consumables	T3	USA	150	2.1	0.3	3.4	86.8
RepligenFiltration/chromatography	T3	USA	80	1.1	0.1	3.3	87.5
IQVIACommercial data/clinical technology services	T3	USA	120	0.6	0.1	1.3	229.5
BASFChemical intermediates	T3	Germany	100	0.5	0.0	1.3	220.6

The calculator ships a researched network for Novartis

This index entry uses calibrated bucket defaults for every supplier's disruption rate, recovery time and revenue-at-risk fraction — the uniform rule applied to all 100 companies — and prices severity pro-rata, by each supplier's share of cost. The ESCRC Calculator ships a researched network for this company ("Novartis"): supplier-specific parameters, priced instead by each supplier's declared criticality — the share of output that halts when it stops. Same engine, same seed, same settings, but two layers differ, the parameters and the severity formula:

SciRisk 100 entry (bucket defaults, pro-rata): $116.3m · 0.258% of revenue
Calculator preset (researched, criticality): $3.32bn · 7.385% of revenue
Ratio: 28.58x

This difference is not a measure of what supplier-level research is worth: it compounds two separate changes, and the formula change is generally the larger of the two. Pro-rata pricing bounds a supplier's loss by its share of cost, so it understates a concentrated, low-spend bottleneck by construction; criticality pricing does not, and rests on declared criticality and unrecoverability values that are operator judgment rather than model outputs. The two figures answer different questions, and neither is used to adjust the other. It is why index figures are labelled preliminary.

Open the ESCRC Calculator

Scenario Analysis — coming in Phase 2

Recovery-time, supplier-diversification, inventory and geographic-diversification scenarios for Novartis are not part of this release. The ESCRC Calculator already supports what-if analysis on a network you build yourself.

Sector peers

Nearest-ranked companies in Pharmaceuticals & Biotechnology. Novartis is highlighted.

Open in Compare

Rank	Company	Ticker	Country	Sector	RevenueUSD bn	ESCRCUSD m	ESCRC / Revenue%	Risk Grade	Change
17	Roche	ROG.SW	Switzerland	Pharmaceuticals & Biotechnology	66.0	137.1	0.208	SC4 High	0.0%
22	AstraZeneca	AZN	United Kingdom	Pharmaceuticals & Biotechnology	54.0	118.9	0.220	SC5 Very High	0.0%
23	Merck & Co.	MRK	USA	Pharmaceuticals & Biotechnology	64.0	118.6	0.185	SC4 High	0.0%
25	Eli Lilly	LLY	USA	Pharmaceuticals & Biotechnology	45.0	116.3	0.259	SC5 Very High	0.0%
26	Novartis	NVS	Switzerland	Pharmaceuticals & Biotechnology	45.0	116.3	0.258	SC5 Very High	0.0%
35	Sanofi	SNY	France	Pharmaceuticals & Biotechnology	47.0	85.9	0.183	SC4 High	0.0%

See this for your own supply chain

You are looking at Novartis's supply-chain risk capital: $116.3m against $45.0bn of revenue, driven mostly by Lonza Group and Switzerland. The calculator runs the same engine on a network you build yourself.

Calculate your ESCRC Load Novartis's network Compare with peers

ESCRC calculated using SciRisk ESCRC Model v5.4.2 · calibrated priors 2026.09-5
Company data as of 2026-06-30 · ESCRC calculated 2026-09-21 · dataset 2026.09-23 Beta

Simulation: 100,000 Monte Carlo paths · 95% confidence · 365-day horizon
Seed: 20260821 · regional correlation ρ = 0.35
Input basis: Curated network, calibrated-prior parameters
Input fingerprint: 3990d88ba115

Input provenance for Novartis

Financials: Production calculator preset focal-firm figures.
Network: Production calculator preset network (Novartis) — supplier names, tiers, geographies, products and purchase volumes as shipped.
Parameters: lambda1/lambda2 = calibrated ESCRC priors 2026.09-5 bucket defaults; r1/r2 = median of the shipped production preset networks within the same industry x geography cell when that cell has enough independent data, else the same industry-only bucket median, or (for industries with no preset supplier coverage) a directly-cited external recovery-event duration where one was found; ic = the same preset-network median (no external benchmark exists for this parameter for any industry). All three clamped into externally-cited recovery-time/BI-loss bounds per field.

SciRisk ESCRC is an analytical estimate generated using the SciRisk Economic Supply Chain Risk Capital methodology. It is not a credit rating, investment recommendation or statement of financial condition. Figures are model-implied and intended for screening and comparison, not as calibrated capital requirements.

Beta / preliminary dataset. Company inputs are analyst-curated from public annual reports and public supply-chain disclosure. ESCRC itself is computed by the production ESCRC engine — only the INPUTS on this page are preliminary.